Preview

Extreme Medicine

Advanced search

Evaluation of avian adenovirus inactivation methods used in the production of influenza vaccines

https://doi.org/10.47183/mes.2021.032

Abstract

Inactivation of influenza virus and other potential contaminants like avian adenoviruses coming from embryonated chicken eggs is a critical step in the production of inactivated influenza vaccines. Inactivation must lead to a guaranteed reduction in contaminant titers by at least 4 lg (PFU)/ml. The aim of this study was to identify an optimum cell line for adenovirus propagation and to estimate a reduction in adenovirus titers in vaccine intermediates after inactivation. In a series of experiments, we identified the optimum conditions and the optimum cell line for the propagation of avian adenovirus (strains CELO and Fontes). The most commonly used inactivation methods were analyzed, including inactivation by β-propiolactone and UV light. Viral titers were measured by plaque assays. After 10 h of inactivation with β-propiolactone, CELO titers fell by 4.12 ± 0.06 lg, whereas Fontes titers, by 4.20 ± 0.19 lg, suggesting that β-propiolactone is an effective inactivating agent. Exposure to UV light led to a reduction in CELO titers by 4.69 ± 0.89 lg and a reduction in Fontes titers by 4.44 ± 1.06 lg after 5 min. N-octyl-β-D-glucopyranoside added at the splitting step reduced CELO titers by 0.93 ± 0.15 lg and Fontes titers by 1.04 ± 0.12 lg, whereas tetradecyltrimethylammonium bromide led to a reduction in CELO and Fontes titers by 1.18 ± 0.17 lg and 1.12 ± 0.38 lg, respectively.

About the Authors

N. N. Savina
Saint Petersburg Research Institute of Vaccines and Serums
Russian Federation

Natalya N. Savina

Svobody, 52, Krasnoye Selo, Saint Petersburg, 198320



A. A. Ekimov
Saint Petersburg Research Institute of Vaccines and Serums
Russian Federation

Svobody, 52, Krasnoye Selo, Saint Petersburg, 198320



V. P. Trukhin
Saint Petersburg Research Institute of Vaccines and Serums
Russian Federation

Svobody, 52, Krasnoye Selo, Saint Petersburg, 198320



A. E. Evtushenko
Saint Petersburg Research Institute of Vaccines and Serums
Russian Federation

Svobody, 52, Krasnoye Selo, Saint Petersburg, 198320



E. N. Zhirenkina
Saint Petersburg Research Institute of Vaccines and Serums
Russian Federation

Svobody, 52, Krasnoye Selo, Saint Petersburg, 198320



E. O. Sinegubova
Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology
Russian Federation

Svobody, 52, Krasnoye Selo, Saint Petersburg, 198320



A. V. Slita
Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology
Russian Federation

Svobody, 52, Krasnoye Selo, Saint Petersburg, 198320



References

1. Guideline on Influenza vaccines — Quality module. EMA/CHMP/BWP/310834/2012 Rev.1 Committee for Medicinal Products for Human use (CHMP), 2017. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-influenzavaccines-quality-module-revision-1_en.pdf.

2. Serija tehnicheskih dokladov VOZ, # 927, 2005 god. Prilozhenie 3. Rekomendacii po proizvodstvu i kontrolju vakcin protiv grippa (inaktivirovannyh). Russian.

3. Sabbaghi A, Miri SM, Keshavarz M, Zargar M, Ghaemi A. Inactivation methods for whole influenza vaccine production. Rev Med Virol. 2019 Nov; 29 (6): e2074.

4. King AMQ, Adams MJ, Carstens EB, Leftkowitc EJ, editors. Virus Taxonomy: Classification and Nomenclature of Viruses. Ninth Report of the International Committee on Taxonomy of Viruses. Elsevier, 2012; 1327 p.

5. Qing Pan, Jing Wang, Yulong Gao, Qi Wang, Hongyu Cui, Changjun Liu, et al. Identification of chicken CAR homology as a cellular receptor for the emerging highly pathogenic fowl adenovirus 4 via unique binding mechanism, Emerging Microbes & Infections. 2020; 9 (1): 586–96.

6. Bakulin V. A., Muryj V. A. Adenovirusnyj gepatit s vkljuchenijamigidroperikardit kur: jepizootologija, diagnostika i specificheskaja profilaktika. Bio. 2011; 12: 28–30. Russian.

7. Borisov VV. Razrabotka sredstv i metodov diagnostiki i specificheskoj profilaktiki adenovirusnyh boleznej kur [dissertacija]. Ivanovo, 2007.

8. Kap M, Arron GI, Loibner M, Hausleitner A, Siaulyte G, Zatloukal K, Riegman P. Inactivation of Influenza A virus, Adenovirus, and Cytomegalovirus with PAXgene Tissue Fixative and Formalin. Biopreservation and Biobanking. 2013; 11 (4): 229–34.

9. Herrera-Rodriguez J, Signorazzi A, Holtrop M, de Vries-Idema J, Huckriede A. Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production. Vaccine. 2019; 37 (12): 1630–7.

10. Shuo Lei, Xun Gao, Yang Sun, Xiangyong Yu, Longshan Zhao. Gas chromatography-mass spectrometry method for determination of β-propiolactone in human inactivated rabies vaccine and its hydrolysis analysis, Journal of Pharmaceutical Analysis. 2018; 8 (6): 373–7.

11. Rukovodstvo po issledovaniju validacii virusnoj ochistki: proektirovanie, vklad i interpretacija issledovanij, ispol'zujushhih inaktivaciju i udalenie virusov. EMA CPMP/BWP/268/95; 1996. Russian.

12. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. The American Journal of Hygiene. 1938; 27: 493–7.

13. Haussmann C, Hauschild F, Jobst B, Novartis AG, assignee. Improvements in preparation of influenza virus vaccine antigens. United States patent US № US6986808P. 18.03.2008.

14. Burt DS, Jones DH, Lowell GH, White GL, Torossian K, Fries LF, assignee. ID Biomedical Corp of Quebec. Proteosome influenza vaccine. United States patent US № US18247600P. 15.02.2000.

15. Truhin VP, Evtushenko AYe, Krasilnikov IV, Savina NN, Bykov DG, Ujba SV, Vasilev AN, Ryskova EV, Nacharova EP, Arakelov SA, avtory; Federal'noe gosudarstvennoe unitarnoe predprijatie «Sankt-Peterburgskij nauchno-issledovatel'skij institut vakcin i syvorotok i predprijatie po proizvodstvu bakterijnyh preparatov» Federal'nogo mediko-biologicheskogo agentstva (FGUP SPbNIIVS FMBA Rossii), patentoobladatel'. Sposob poluchenija antigena ili antigenov dlja proizvodstva protivogrippoznoj vakciny i vakcina na ego osnove. Patent RF # RU2019118695A. 14.06.2019. Russian.


Review

For citations:


Savina N.N., Ekimov A.A., Trukhin V.P., Evtushenko A.E., Zhirenkina E.N., Sinegubova E.O., Slita A.V. Evaluation of avian adenovirus inactivation methods used in the production of influenza vaccines. Extreme Medicine. 2021;23(3):84-89. https://doi.org/10.47183/mes.2021.032

Views: 15


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2713-2757 (Print)
ISSN 2713-2765 (Online)